Prevalence of thrombophilic mutations and ACE i/d polymorphism in turkish ischemic stroke patients

Clinical and Applied Thrombosis/Hemostasis

Volumn 15, Issue 4, 2009, Pages 415-420

  Celiker, Gulay ^a   Can, Ufuk ^a   Verdi, Hasibe ^a   Yazici, Ayse Canan ^a   Ozbek, Namik ^a   Atac, Fatma Belgin ^a  

^a BASKENT UNIVERSITY   (Turkey)

Author keywords

Coagulation factors; Ischemic stroke

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); BLOOD CLOTTING FACTOR 5 LEIDEN; DIPEPTIDYL CARBOXYPEPTIDASE; PROTHROMBIN;

ADULT; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; GENE FREQUENCY; GENE MUTATION; GENOTYPE; HETEROZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; THROMBOPHILIA;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; BRAIN ISCHEMIA; BUTORPHANOL; FACTOR V; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HUMANS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; PEPTIDYL-DIPEPTIDASE A; POLYMORPHISM, GENETIC; PREVALENCE; PROTHROMBIN; RISK FACTORS; STROKE; THROMBOPHILIA; TURKEY; YOUNG ADULT;

EID: 69749107078     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/1076029608315163     Document Type: Article

References (42)

1. Tournier-Laserve E. New players in the genetic of stroke. N Eng J Med. 2002 ; 347: 1711-1712.
2. Gao X., Yang H., ZhiPing T. Association studies of genetic polymorphism, environmental factors and their interaction in ischemic stroke. Neurosci Lett. 2006 ; 398: 172-177.
3. Bezemer ID, Rosendaal FR Predictive genetic variants for venous thrombosis: what's new ? Semin Hematol. 2007 ; 44: 85-92.
4. Dahlb̈k B., Carlsson M., Svensson PJ Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C. Proc Natl Acad Sci. 1993 ; 90: 1004-1008.
5. Atac B., Yakupoglu U., Ozbek N., Ozdemir FN, Bilgin N. Role of genetic mutations in vascular access thrombosis among hemodialysis patients waiting for renal transplantation. Transplant Proc. 2002 ; 34: 2030-2032.
6. Slowik A., Dziedzic T., Pera J., Wloch D., Kopec G., Szczudlik A. ACE genotype, risk and causal relationship to stroke: implications for treatment. Curr Treat Options Cardiovasc Med. 2007 ; 9: 198-204.
7. Carluccio M., Soccio M., de Caterina R. Aspects of gene polymorphism in cardiovascular disease: the renin-angiotensin system. Eur J Clin Invest. 2001 ; 31: 476-488.
8. Adams HP, Bendixen BH, Keppelle J., et al. Classification of ischemic stroke: definition for use in a multicenter clinical trial. Stroke. 1993 ; 24: 35-41.
9. Miller SA, Dykes DD, Polesky HS A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988 ; 16: 1215.
10. De Stefano V., Zappacosta B., Persichilli S., et al. Prevalence of mild hyperhomocysteinaemia and association with thrombophilic genotypes (factor V Leiden and prothrombin G20210A) in Italian patients with venous thromboembolic disease. Br J Haematol. 1999 ; 106: 564-568.
11. Akar N., Akar E., Akçay R., Avcu F., Yalççn A., Cin S. Effect of methylenetetrahydrofolate reductase 677 C-T, 1298 A-C, and 1317 T-C on factor V 1691 mutation in Turkish deep vein thrombosis patients. Thromb Res. 2000 ; 97: 163-167.
12. Lovati E., Richard A., Frey BM, Frey FJ, Ferrari P. Genetic polymorphisms of the renin-angiotensin-aldosterone system in end-stage renal disease. Kidney Int. 2001 ; 60: 46-54.
13. Akar N., Akar E., Dalgln G., Sözüöz A., Ömürlü K., Cin S. Frequency of Factor V (1691 G>A) mutation in Turkish population. Thromb Haemost. 1997 ; 78: 1527-1529.
14. Akar N., Mlslrlloglu M., Akar E. Prothrombin gene 20210 G-A mutation in the Turkish population. Am J Haematol. 1998 ; 58: 249.
15. Akar N., Akar E., Deda G., Sipahi T., Orsal A. Factor V1691 G-A, prothrombin 20210 G-A, and methylenetetrahydrofolate reductase 677 C-T variants in Turkish children with cerebral infarct. J Child Neurol. 1999 ; 14: 749-1751.
16. Akar N., Aras Ö., Ömürlü K., Cin S. Deletion polymorphism at the angiotensin-converting enzyme gene in Turkish patients with coronary artery disease. Scand J Clin Lab Invest. 1998 ; 58: 491-496.
17. Lovett JK, Coull AJ, Rothwell PM Early risk of recurrence by subtype of ischemic stroke in population-based incidence studies. Neurology. 2004: 62 ; 569-573.
18. Sharma P. Meta-analysis of the ACE gene ischaemic stroke. J Neurol Neurosurg Psychiatry. 1998 ; 64: 227-230.
19. Markus HS, Barley J., Lunt R., et al. Angiotensin converting enzyme gene deletion polymorphism: a new risk factor for lacuner stroke but no carotid atheroma. Stroke. 1995 ; 26: 1329-1333.
20. Nakata Y., Katsuya T., Rakugi H., et al. Polymorphism of angiotensin-converting enzyme, angiotensinogen, and Apolipoprotein E genes in a Japanese population with cerebrovascular disease. Am J Hypertens. 1997 ; 12: 1391-1395.
21. Doi Y., Yoshinari M., Yoshizumi H., Ibayashi S., Wakisaka M., Fujishima M. Polymorphism in the angiotensin- converting enzyme (ACE) gene in patients with thrombotic brain infarction. Atherosclerosis. 1997 ; 132: 145-150.
22. Kario K., Kanai N., Saito K., Nago N., Takefumi M., Shimada K. Ischemic stroke and the gene for angiotensin-converting enzyme in Japanese hypertensives. Circulation. 1996 ; 93: 1630-1633. (Pubitemid 26131337)
23. Watanabe Y., Ishigami T., Kawano Y., et al. Angiotensin-converting enzyme gene I/D polymorphism and carotid plaques in Japanese. Hypertension. 1997 ; 30: 569-573.
24. Castellano M., Muiesan ML, Rizzoni D., et al. Angiotensin-converting enzyme I/D polymorphism and arterial wall thickness in a general population. Circulation. 1995 ; 91: 2721-2724.
25. Reed DC, Cox M., Clegg JB World distribution of factor V Leiden. Lancet. 1995 ; 346: 1133-1134.
26. Rosendaal FR, Koster T., Vandenbroucke JP, Reistma PH High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood. 1995 ; 85: 1504-1508.
27. Alboucher JF, Guirand-Chaumeil B., Chollet F., Cadroy Y., Sie P. Frequency of resistance to activated protein C due to factor V mutation in young patients with ischaemic stroke (letter). Stroke. 1996 ; 27: 766-767.
28. Chimowitz M., Mansbach H., Schmaier A. Factor V mutation and cryptogenic stroke in the young [abstract]. Stroke. 1996 ; 27: 188.
29. Catto A., Carter A., Ireland H., et al. Factor V Leiden gene mutation and thrombin generation in relation to the development of acute stroke. Arterioscler Thromb Vasc Biol. 1995 ; 15: 783-785.
30. Ridker PM, Hennekens CH, Lidpaintner K., Stampfer MJ, Elsenberg PR, Miletich JP Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke and venous thrombosis in apparently healthy men. N Engl J Med. 1995 ; 332: 912-917.
31. Fisher M., Fernandez JA, Ameriso SF, et al. Activated protein C resistance in ischemic stroke not due to factor V arginine506ĝ† 'glutamine mutation. Stroke. 1996 ; 27: 1163-1166.
32. Press RD, Liu XY, Beamer N., Coull BM Ischemic stroke in the elderly: role of the common factor V mutation causing resistance to activated protein C. Stroke. 1996 ; 27: 44-48.
33. Sánchez J., Román J., de la Torre M., Velasco F., Torres A. Low prevalance of the factor V Leiden among patients with ischemic stroke. Haemostasis. 1997 ; 27: 9-15.
34. Longstreth WT, Rosendaal FR, Siscovick DS, et al. Risk of stroke in young women and two prothrombotic mutation: factor V Leiden and prothrombin gene variant (G20210A). Stroke. 1998 ; 29: 577-580.
35. Markus HS, Zhang Y., Jeffery S. Screening for the factor V Arg506 Gln mutation in patients with TIA and stroke. Cerebrovasc Dis. 1996 ; 6: 360-362.
36. Rosendaal FR, Doggen CJ, Zivelin A., et al. Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost. 1998 ; 79: 706-708.
37. Cumming AM, Keeney S., Salden A., Bhavnani M., Shwe K., Hay CRM. The prothrombin gene G20210A variant: prevalance in a U.K. anticoagulant clinic population. Br J Haemotol. 1997 ; 98: 353-355.
38. De Stefano V., Chiusulo P., Paciaroni K., et al. Prothrombin G20210A mutation genotype is a risk factor for cerebrovascular ischemic disease in young patients. Blood. 1998 ; 91: 3562-3565.
39. Martinelli I., Franchi F., Akwan S., Bettini P., Merati G., Mannucci PM The transition G to A at position 20210 in the 3' untranslated region of the prothrombin gene is not associated with cerebral ischaemia. Blood. 1997 ; 29: 3806.
40. Perry IJ, Refsum H., Morris RW, Ebrahim SB, Ueland PM, Shaper AG Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet. 1995 ; 346: 395-398.
41. Markus HS, Ali N., Swaminathan R., Sankaralingam A., Molloy J., Powell J. A common polymorphism in the methylentetrahydrofolate reductase gene, homocysteine, and ischemic cerebrovascular disease. Stroke. 1997 ; 28: 1739-1743.
42. Nakata Y., Katsuya T., Takami S., et al. Methylenetetrahydrofolate reductase gene polymorphism: relation to blood pressure and cerebrovascular disease. Am J Hypertens. 1998 ; 11: 1019-1023.